Vitamin D and physical activity in patients with colorectal cancer: Epidemiological evidence and therapeutic implications

Cancer Journal (United States)

Volumn 22, Issue 3, 2016, Pages 223-231

  Morales Oyarvide, Vicente ^a   Meyerhardt, Jeffrey A ^a   Ng, Kimmie ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Colorectal cancer; Metastatic; Physical activity; Vitamin D

Indexed keywords

BEVACIZUMAB; COLECALCIFEROL; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SLEEP QUALITY; ANIMAL; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; EXERCISE; METABOLISM; MORTALITY; TREATMENT OUTCOME;

ANIMALS; CLINICAL STUDIES AS TOPIC; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; EXERCISE; HUMANS; TREATMENT OUTCOME; VITAMIN D;

EID: 84978286649     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000197     Document Type: Review

References (70)

1. Colon/Rectum Cancer /American Cancer Society [Internet]. American Cancer Society, Inc; 2006. Available at: http://www.cancer.org/cancer/colonandrectumcancer/index. Accessed on March 3, 2016.
2. Cancer of the Colon and Rectum-SEER Cancer Stat Fact Sheets [Internet] National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/colorect.html. Accessed on March 3, 2016.
3. Venook AP, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum. J ClinOncol. 2014;32(4s (suppl 15 s; abstr LBA3)).
4. Ng K, Wolpin BM, Meyerhardt JA, et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009;101:916-923.
5. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys. 2012;523:123-133.
6. Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normalmucosa. Cancer Res. 1991;51:1227-1233.
7. ShabahangM, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues 1,25-dihydroxyvitamin D3. Cancer Res. 1994;54:4057-4064.
8. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987;47:21-25.
9. Huerta S, Irwin RW, Heber D, et al. 1alpha,25-(OH)(2)-D3 and its synthetic analogue decrease tumor load in the Apc(min) mouse. Cancer Res. 2002; 62:741-746.
10. Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer. 2010;126:631-639.
11. Diaz GD, Paraskeva CT, Binderup L, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000;60:2304-2312.
12. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14:342-357.
13. MathieuC,Adorini L. The coming of age of 1,25-dihydroxyvitaminD(3) analogs as immunomodulatory agents. Trends Mol Med. 2002;8:174-179.
14. Scaglione-Sewell BA, BissonnetteM, Skarosi S, et al. Avitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology. 2000;141:3931-3939.
15. Iseki K, TatsutaM, Uehara H, et al. Inhibition of angiogenesis as a mechanismfor inhibition by 1alpha-hydroxyvitamin D3 and 1,25-hydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer. 1999;821:730-733.
16. Lamprecht SA, Lipkin M. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci. 2001;952: 73-87.
17. Aggarwal A, Hoebaus J, Tennakoon S, et al. Active vitamin D potentiates the anti-neoplastic effects of calcium in the colon: a cross-talk through the calcium-sensing receptor. J Steroid Biochem Mol Biol. 2016;155(Pt B): 231-238.
18. Braun MM, Helzlsouer KJ, Hollis BW, et al. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol. 1995;142:608-611.
19. Grant WB. Ecological studies of the UVB-vitamin D-cancer hypothesis. Anticancer Res. 2012;32:223-236.
20. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2004; 13:1502-1508.
21. Maalmi H, Ordoñez-Mena JM, Schöttker B, et al. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer. 2014;50:1510-1521.
22. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684-696.
23. Lappe J, Travers-Gustafson D, Daviers KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586-1591.
24. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326:469-472.
25. Baron JA, Barry EL, Mott LA, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med. 2015;373: 1519-1530.
26. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626-632.
27. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calciumand vitaminD from the Institute ofMedicine: what clinicians need to know. J Clin EndocrinolMetab. 2011;96:53-58.
28. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin EndocrinolMetab. 2011;96:1911-1930.
29. Ng K,Meyerhardt JA,Wu K, et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26: 2984-2991.
30. Mezawa H, Sugiura T,Watanabe M, et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer. 2010;10:347.
31. Ng K, Sargent DJ, Goldberg RM, et al. Vitamin D status in patients with stage IV colorectal cancer: findings from intergroup trial N9741. J Clin Oncol. 2011;29:1599-1606.
32. Fedirko V, Riboli E. Tjonneland et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev. 2012;21:582-593.
33. Tretli S, Schwartz GG, Torjesen PA, et al. Serum levels of 25-hydroxyvitaminDand survival inNorwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23:363-370.
34. Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32:2430-2439.
35. Yang B, McCullough ML, Gapstur SM, et al. Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2014;32:2335-2343.
36. Jeffreys M, Redaniel MT, Martin RM. The effect of pre-diagnostic vitamin D supplementation on cancer survival in women: a cohort study within the UK Clinical Practice Research Datalink. BMC Cancer. 2015;15:670.
37. NgK, Venook AP, Sato K, et al. Vitamin D status and survival of metastatic colorectal cancer patients: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2015;33(suppl 3; abstr 507).
38. Mohr SB, Gorham ED, Kim J, et al. Could vitamin D sufficiency improve the survival of colorectal cancer patients? J Steroid Biochem Mol Biol. 2015;148:239-244.
39. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.
40. Fakih MG, Andrews C, McMahon J, et al. A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: evidence of a chemotherapy-response interaction. Anticancer Res. 2012;32:1333-1338.
41. Samad AK, Taylor RS, Marshall T, et al. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005;7:204-213.
42. Betof AS, Dewhirst MW, Jones LW. Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. Brain Behav Immun. 2013;30:S75-S87.
43. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patientswith stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535-3541.
44. McClellan JL, Steiner JL, Day SD, et al. Exercise effects on polyp burden and immune markers in the Apcmin/+ mouse model of intestinal tumorigenesis. Int J Oncol. 2014;45:861-868.
45. Aoi W, Naito Y, Takagi T, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013;62:882-889.
46. Je Y, Jeon JY, Giovannucci EL, et al. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer. 2013;133:1905-1913.
47. Meyerhardt JA, Giovannucci EL, HolmesMD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24:3527-3534.
48. Meyerhardt JA, Giovannuci EL, Ogino S, et al. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009;169:2102-2108.
49. Baade PD, Meng X, Youl PH, et al. The impact of bodymass index and physical activity on mortality among patientswith colorectal cancer in Queensland, Australia. Cancer Epidemiol Biomarkers Prev. 2011;20:1410-1420.
50. Kuiper JG, Phipps AI, Neuhouser ML, et al. Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control. 2012;23:1939-1948.
51. Campbell PT, Patel AV, Newton CC, et al. Associations of recreational physical activity and leisure time spent witting with colorectal cancer survival. J Clin Oncol. 2013;31:876-885.
52. AremH, Pfeiffer RM, Engels EA, et al. Pre-and postdiagnosis physical activity, television viewing, and mortality among patients with colorectal cancer in the National Institutes of Health-AARP diet and health study. J Clin Oncol. 2015;33:180-188.
53. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25:1293-1311.
54. Meyerhardt JA, Ogino S, Kirkner GJ, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009;15:5931-5936.
55. Morikawa T, Kuchiba A, Yamauchi M, et al. Associations of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305:1685-1694.
56. Yamauchi M, Lochhead P, Imamura Y, et al. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1142-1152.
57. Hanyuda A, Kim SA, Martinez-Fernandez A, et al. Survival benefit of exercise differs by tumor IRS1 expression status in colorectal cancer. Ann Surg Oncol. 2015;23:908-917.
58. Ligibel JA,Meyerhardt J, Pierce JP, et al. Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. Breast Cancer Res Treat. 2012;132:205-213.
59. Pinto BM, Papandonatos GD, Goldstein MG, et al. Home-based physical activity intervention for colorectal cancer survivors. Psychooncology. 2013;22:54-65.
60. Lee DH, Kim JY, Lee MK, et al. Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. Support Care Cancer. 2013;21: 2537-2545.
61. Courneya KS, Fredenreich CM, Quinney HA, et al. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care. 2003;12:347-357.
62. Backman M, Wengström Y, Johansson B, et al. A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol. 2014;53:510-520.
63. Cheville AL, Kollasch J, Vandenberg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013;35:811-821.
64. Devin JL, Sax AT, Hughes GI, et al. The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial. J Cancer Surviv. 2015; [published online ahead of print October 19, 2015].
65. Park JH, Lee J, OhM, et al. The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: a randomized controlled trial. Cancer. 2015;121: 2740-2748.
66. Lynch BM, Courneya KS, Sethi P, et al. A randomized controlled trial of a multiple health behavior change intervention delivered to colorectal cancer survivors. Effects on sedentary behavior. Cancer. 2014;120:2665-2672.
67. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25:4396-4404.
68. Courneya KS, Friedenreich CM, Sela R, et al. Correlates of adherence and contamination in a randomized trial of exercise in cancer survivors: an application of the theory of planned behavior and the five factormodel of personality. Ann Behav Med. 2002;24:257-268.
69. Fuchs CS, Goldberg RM, Sargent DJ, et al. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008;14: 8263-8269.
70. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among peoplewith type 2 diabetes. Diabetes Care. 2009;32:1620-1625.